Display options
Cite
Yoshioka C, Ito Y, Nagai N. Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism. Exp Ther Med. 2018;15(4):3501-3508doi: 10.3892/etm.2018.5820.
Yoshioka, C., Ito, Y., & Nagai, N. (2018). Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism. Experimental and therapeutic medicine, 15(4), 3501-3508. https://doi.org/10.3892/etm.2018.5820
Yoshioka, Chiaki, et al. "Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism." Experimental and therapeutic medicine vol. 15,4 (2018): 3501-3508. doi: https://doi.org/10.3892/etm.2018.5820
Yoshioka C, Ito Y, Nagai N. Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism. Exp Ther Med. 2018 Apr;15(4):3501-3508. doi: 10.3892/etm.2018.5820. Epub 2018 Jan 31. PMID: 29545875; PMCID: PMC5840931.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2018 Apr;15(4):3501-3508. doi: 10.3892/etm.2018.5820. Epub 2018 Jan 31.

Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism.

Experimental and therapeutic medicine

Chiaki Yoshioka, Yoshimasa Ito, Noriaki Nagai

Affiliations

  1. Faculty of Pharmacy, Kindai University, Higashi-Osaka, Osaka 577-8502, Japan.

PMID: 29545875 PMCID: PMC5840931 DOI: 10.3892/etm.2018.5820

Abstract

Cilostazol (CLZ), an anti-platelet agent, is primarily used following the onset of cerebral infarction. However, as CLZ is only marginally soluble in water, a strategy for patients with serious secondary conditions, such as impaired consciousness or aphagia, is required. In the present study, topical formulations containing CLZ nanocrystals (CLZ

Keywords: absorption mechanism; aqueous gel patch; cilostazol; nanocrystal

References

  1. J Biomed Nanotechnol. 2010 Feb;6(1):20-7 - PubMed
  2. J Invest Dermatol. 1965 Nov;45(5):334-46 - PubMed
  3. J Control Release. 2010 Feb 15;141(3):277-99 - PubMed
  4. Curr Pharm Des. 2003;9(28):2289-302 - PubMed
  5. Exp Ther Med. 2018 Jan;15(1):454-460 - PubMed
  6. ACS Nano. 2010 Oct 26;4(10 ):5887-96 - PubMed
  7. J Invest Dermatol. 1975 Mar;64(3):190-5 - PubMed
  8. J Control Release. 2011 Nov 7;155(3):344-57 - PubMed
  9. Nat Biotechnol. 2004 Aug;22(8):969-76 - PubMed
  10. J Invest Dermatol. 2012 Mar;132(3 Pt 2):964-75 - PubMed
  11. Drug Discov Today Technol. 2005 Spring;2(1):67-74 - PubMed
  12. Arzneimittelforschung. 1985;35(7A):1144-9 - PubMed
  13. J Control Release. 2006 Mar 10;111(1-2):56-64 - PubMed
  14. Chem Soc Rev. 2009 Jun;38(6):1759-82 - PubMed
  15. Mol Pharm. 2009 Mar-Apr;6(2):520-30 - PubMed
  16. J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):147-57 - PubMed
  17. Clin Pharmacokinet. 1999;37 Suppl 2:13-23 - PubMed
  18. Biol Pharm Bull. 2015;38(12):1918-24 - PubMed
  19. J Control Release. 2010 Dec 20;148(3):266-82 - PubMed
  20. Pharm Dev Technol. 2004;9(1):1-13 - PubMed
  21. Pharm Dev Technol. 2011 Oct;16(5):497-510 - PubMed
  22. FASEB J. 2005 Mar;19(3):311-30 - PubMed
  23. J Control Release. 2008 Aug 25;130(1):29-37 - PubMed
  24. Toxicol Appl Pharmacol. 2008 Apr 15;228(2):200-11 - PubMed
  25. Curr Pharm Des. 2009;15(2):153-72 - PubMed

Publication Types